Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Allos Therapeutics, Inc. (NasdaqNM:ALTH)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Location
7000 North Broadway, Suite 400
Denver, CO 80221
Phone: (303) 426-6262
Fax: (303) 412-9160
Email: info@allos.com
Employees (last reported count): 45
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 57%
·Institutional: 41% (94% of float)
(75 institutions)
·Net Inst. Buying: 3.67M shares (+28.28%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Allos Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small molecule drugs, initially for improving cancer treatments. The Company's lead product candidate is RSR13, a synthetic small molecule that increases the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells. RSR13 may be used to improve existing cancer treatments, and treat many diseases and clinical conditions attributed to or aggravated by oxygen deprivation, or hypoxia.
More from Market Guide: Expanded Business Description

Financial Summary
Allos Therapeutics is a pharmaceutical company focused on developing and commercializing innovative small molecule drugs, initially for improving cancer treatments. For the six months ended 6/30/01, the company reported no revenue. Net loss fell 35% to $9.6 million. Results reflect lower amortization of deferred stock compensation expenses and the absence of a $7.6 million stock compensation expense resulting from the forgiveness of notes receivable.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Stephen Hoffman, Ph.D., M.D., 46
Pres, CEO, Director
$391K
Michael Hart, 48
Sr. VP, Operations, CFO
287K
Michael Gerber, M.D., 48
Sr. VP, Clinical Devel. and Regulatory Affairs
356K
Markus Herzig, 56
VP of Regulatory Affairs
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ALTHAs of 31-Aug-2001
Price and Volume
52-Week Low
on 19-July-2001
$4.25 
Recent Price$5.39 
52-Week High
on 7-Sep-2000
$12.375
Daily Volume (3-month avg)103.4K
Daily Volume (10-day avg)161.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-51.0%
52-Week Change
relative to S&P500
-34.3%
Share-Related Items
Market Capitalization$123.7M
Shares Outstanding23.0M
Float9.90M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.29 
Earnings (ttm)-$0.80 
Earnings (mrq)-$0.23 
SalesN/A 
Cash (mrq)$2.66 
Valuation Ratios
Price/Book (mrq)1.64 
Price/EarningsN/A 
Price/SalesN/A 
Income Statements
Sales (ttm)$0 
EBITDA (ttm)-$18.3M
Income available to common (ttm)-$18.2M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-21.24%
Return on Equity (ttm)-21.98%
Financial Strength
Current Ratio (mrq)12.71 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$61.0M
Short Interest
As of 8-Aug-2001
Shares Short6,000 
Percent of Float0.1%
Shares Short
(Prior Month)
7,000 
Short Ratio0.07 
Daily Volume93.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.